542 related articles for article (PubMed ID: 16826577)
21. Histone deacetylase inhibitors: multifunctional anticancer agents.
Liu T; Kuljaca S; Tee A; Marshall GM
Cancer Treat Rev; 2006 May; 32(3):157-65. PubMed ID: 16516391
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
Riester D; Hildmann C; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
[TBL] [Abstract][Full Text] [Related]
23. HDAC inhibitors: a potential new category of anti-tumor agents.
Pan LN; Lu J; Huang B
Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic regulation of airway inflammation.
Adcock IM; Tsaprouni L; Bhavsar P; Ito K
Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
[TBL] [Abstract][Full Text] [Related]
28. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
Murgo AJ
Semin Oncol; 2005 Oct; 32(5):458-64. PubMed ID: 16210086
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic drugs take on cancer.
Kaiser J
Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
[No Abstract] [Full Text] [Related]
30. The critical role of the class III histone deacetylase SIRT1 in cancer.
Liu T; Liu PY; Marshall GM
Cancer Res; 2009 Mar; 69(5):1702-5. PubMed ID: 19244112
[TBL] [Abstract][Full Text] [Related]
31. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.
Hess-Stumpp H; Bracker TU; Henderson D; Politz O
Int J Biochem Cell Biol; 2007; 39(7-8):1388-405. PubMed ID: 17383217
[TBL] [Abstract][Full Text] [Related]
32. Histone modifications as a platform for cancer therapy.
Espino PS; Drobic B; Dunn KL; Davie JR
J Cell Biochem; 2005 Apr; 94(6):1088-102. PubMed ID: 15723344
[TBL] [Abstract][Full Text] [Related]
33. [Histone deacetylases: a new class of efficient anti-tumor drugs].
Mottet D; Castronovo V
Med Sci (Paris); 2008; 24(8-9):742-6. PubMed ID: 18789222
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Piekarz RL; Sackett DL; Bates SE
Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
[TBL] [Abstract][Full Text] [Related]
35. H3K9 acetylation and radial chromatin positioning.
Strasák L; Bártová E; Harnicarová A; Galiová G; Krejcí J; Kozubek S
J Cell Physiol; 2009 Jul; 220(1):91-101. PubMed ID: 19248079
[TBL] [Abstract][Full Text] [Related]
36. HDAC inhibitors: clinical update and mechanism-based potential.
Glaser KB
Biochem Pharmacol; 2007 Sep; 74(5):659-71. PubMed ID: 17498667
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
38. Targeted histone deacetylase inhibition for cancer therapy.
Vigushin DM; Coombes RC
Curr Cancer Drug Targets; 2004 Mar; 4(2):205-18. PubMed ID: 15032670
[TBL] [Abstract][Full Text] [Related]
39. [Development of HDAC inhibitors].
Sowa Y
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1665-8. PubMed ID: 20841929
[TBL] [Abstract][Full Text] [Related]
40. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
